Fiduciary Group LLC Has $8.09 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fiduciary Group LLC trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,976 shares of the medical equipment provider’s stock after selling 295 shares during the quarter. Intuitive Surgical makes up about 0.9% of Fiduciary Group LLC’s portfolio, making the stock its 27th largest holding. Fiduciary Group LLC’s holdings in Intuitive Surgical were worth $8,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. WCM Investment Management LLC bought a new position in Intuitive Surgical in the 4th quarter valued at approximately $575,536,000. International Assets Investment Management LLC lifted its holdings in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd grew its stake in shares of Intuitive Surgical by 113.2% in the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after purchasing an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Intuitive Surgical in the third quarter valued at $178,667,000. Finally, Quadrature Capital Ltd increased its holdings in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after purchasing an additional 280,480 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $2.21 during mid-day trading on Friday, hitting $375.33. 927,845 shares of the stock were exchanged, compared to its average volume of 1,564,565. The company has a market capitalization of $133.13 billion, a P/E ratio of 67.75, a P/E/G ratio of 4.85 and a beta of 1.36. The company has a 50-day simple moving average of $386.19 and a 200 day simple moving average of $346.29. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period last year, the firm posted $1.00 EPS. Analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CEO Gary S. Guthart sold 24,325 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the completion of the transaction, the chief executive officer now owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Gary S. Guthart sold 24,325 shares of Intuitive Surgical stock in a transaction on Monday, January 29th. The stock was sold at an average price of $376.06, for a total value of $9,147,659.50. Following the completion of the transaction, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold a total of 249,418 shares of company stock worth $96,300,959 over the last ninety days. 0.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ISRG shares. Raymond James increased their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Mizuho raised their target price on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.